Published in J Clin Oncol on June 04, 2012
Systems biology of cisplatin resistance: past, present and future. Cell Death Dis (2014) 1.74
Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One (2015) 1.46
Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41
New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials. Cancer Manag Res (2015) 1.19
New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J Pathol (2013) 1.15
Systemic treatments for mesothelioma: standard and novel. Curr Treat Options Oncol (2008) 1.07
Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. Clin Chest Med (2013) 0.98
Advances in the diagnosis, treatment and prognosis of malignant pleural mesothelioma. Ann Transl Med (2015) 0.95
Malignant pleural mesothelioma: current and future perspectives. J Thorac Dis (2013) 0.91
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin. Br J Cancer (2011) 0.91
Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer (2012) 0.89
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer (2013) 0.89
Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future. Ann Cardiothorac Surg (2012) 0.87
Hispanic accrual on randomized cancer clinical trials: a call to arms. J Clin Oncol (2014) 0.85
Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol (2014) 0.85
EphB4 as a therapeutic target in mesothelioma. BMC Cancer (2013) 0.84
Current issues in malignant pleural mesothelioma evaluation and management. Oncologist (2014) 0.81
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. Int J Clin Oncol (2013) 0.81
Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med (2015) 0.81
Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol (2016) 0.79
Diagnosis and management of patients with malignant peritoneal mesothelioma. J Gastrointest Oncol (2016) 0.79
The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma. BMC Cancer (2015) 0.76
Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer (2017) 0.75
Management of malignant pleural mesothelioma-part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG). Wien Klin Wochenschr (2016) 0.75
Modern management of malignant pleural mesothelioma. Lung Cancer (Auckl) (2016) 0.75
Malignant peritoneal mesothelioma. Is there a new treatment? Rare Tumors (2009) 0.75
Mesothelioma treatment: Are we on target? A review. J Adv Res (2014) 0.75
Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. Genes Cancer (2016) 0.75
Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date. Onco Targets Ther (2017) 0.75
Cerebral Blood Flow Changes in Glioblastoma Patients Undergoing Bevacizumab Treatment Are Seen in Both Tumor and Normal Brain. Neuroradiol J (2015) 0.75
Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma. Oncotarget (2016) 0.75
Recommended Readings from the University of Oxford Respiratory Trials Unit Research Fellows. Am J Respir Crit Care Med (2017) 0.75
Malignant peritoneal mesothelioma: a review. Ann Transl Med (2017) 0.75
Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. ESMO Open (2017) 0.75
Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis. Eur J Clin Pharmacol (2015) 0.75
Optimal Therapy of Advanced Stage Mesothelioma. Curr Treat Options Oncol (2017) 0.75
Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget (2017) 0.75
A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma. Lung Cancer (Auckl) (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol (2003) 11.22
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol (2008) 6.23
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol (2010) 5.21
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell (2008) 4.51
Prognosis of cancers associated with venous thromboembolism. N Engl J Med (2000) 4.51
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol (2010) 3.40
Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol (2005) 3.36
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol (1999) 2.25
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest (1998) 2.18
Malignant pleural mesothelioma. J Clin Oncol (2009) 2.16
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol (1998) 2.15
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer (1999) 1.86
Phase II trials in journal of clinical oncology. J Clin Oncol (2009) 1.78
Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol (2001) 1.41
Update on malignant pleural mesothelioma. Semin Respir Crit Care Med (2011) 1.30
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer (2002) 1.20
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer (2002) 1.10
Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res (1998) 1.03
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307. J Thorac Oncol (2010) 1.02
Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer (2008) 0.99
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer (2007) 0.96
Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol (2005) 0.96
Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer (2004) 0.94
Vatalanib in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer (2011) 0.92
Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. Br J Cancer (2011) 0.91
Issues in designing sequential stopping rules for monitoring side effects in clinical trials. Control Clin Trials (1987) 0.88
Antiangiogenic therapies for mesothelioma. Hematol Oncol Clin North Am (2005) 0.86
Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma. Lung Cancer (2006) 0.85
The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol (2002) 0.81
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature (2012) 14.33
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med (2015) 12.54
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med (2015) 11.98
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med (2003) 11.35
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
The origin and evolution of mutations in acute myeloid leukemia. Cell (2012) 9.66
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol (2012) 8.64
Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature (2005) 8.55
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res (2008) 6.91
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med (2010) 6.28
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol (2008) 6.23
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol (2009) 5.70
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res (2004) 5.23
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst (2007) 5.13
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol (2008) 5.11
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol (2010) 5.08
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol (2004) 5.06
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol (2008) 5.04
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol (2010) 4.81
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol (2004) 4.77
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol (2004) 4.67
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res (2010) 4.51
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med (2011) 4.51
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys (2006) 4.22
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst (2005) 4.19
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res (2006) 4.11
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol (2007) 3.85
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol (2008) 3.83
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65
Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol (2006) 3.59
Frequency of failure to inform patients of clinically significant outpatient test results. Arch Intern Med (2009) 3.55
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol (2007) 3.50